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INVESTIGATION OF UNCHARACTERIZED SPONDYLOCOSTAL 
DYSOSTOSIS USING WHOLE EXOME SEQUENCING 
 
THEODORE B. DOHERTY 
ABSTRACT 
Skeletal dysplasias and dysostoses are a genotypically and phenotypically diverse 
group of disorders that affect the growth, development and maintenance of cartilage and 
bone. General disorders of bone affecting bones and cartilage throughout the body have 
been referred to as skeletal dysplasias, whereas defects that selectively affect certain 
bones or bone groups are called skeletal dysostoses. Despite this distinction, modern 
molecular techniques are showing that this division is somewhat superficial, given the 
similarity in their underlying causes. Although the rate of disease gene discovery has 
grown substantially since the advent of next-generation sequencing technologies, most of 
the disorders have unknown molecular defects.  
Skeletal dysostoses are rarely observed, occurring at such low incidence levels 
that no comprehensive study has ascertained their frequency. The effects range from mild 
growth inhibition to complete absence of entire bone groups. The axial skeleton is most 
often involved in skeletal dysostoses with common symptoms including poorly formed 
cranial bones, mandible, ribs and vertebrae. Several important signaling pathways control 
the migration and formation of mesodermal cells, which eventually differentiate into 
many elements of the vertebral column. The importance of these pathways, namely the T-
  vi 
box transcription factors, Wnt, Notch, and Smad pathways are integrally involved in the 
very early stages of vertebral development.  
Currently, the most cost-effective method of pathogenic gene discovery for rare 
genetic diseases is exome sequencing. Utilizing this technology, as well as SNP arrays 
for identity-by-descent loci mapping, two independent skeletal dysostosis cases with 
similar phenotypes were studied to determine pathogenic candidate genes. Next-
generation sequencing and identity-by-descent analysis revealed a possible candidate 
gene, PM20D2, in one proband. The gene includes peptidase dimerization, peptidase 
M20/M25/M40, and N-myristolylation domains based on predicted functional analysis. It 
is implicated in various metabolic activities, having hydrolase, protein binding, and 
metallopeptidase molecular functions. Further investigation into this gene, as well as 
further studies of these probands is needed to understand the role, if any, the defect plays 
in the disease.  
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INTRODUCTION 
 
Skeletal dysplasias and dysostoses 
Skeletal dysplasias are a genotypically and phenotypically diverse group of 
disorders that affect the growth, development and maintenance of cartilage and bone. 
Currently, the International Skeletal Dysplasia Society recognizes more than 350 distinct 
bone dysplasias clustered into 32 disease groups based on molecular, biomolecular, and 
radiographic similarities
1
. Of these disorders, 316 have been associated with changes in 
226 genes
1
. General disorders of bone affecting bones and cartilage throughout the body 
have been referred to as skeletal dysplasias, whereas defects that selectively affect certain 
bones or bone groups are called skeletal dysostoses
2
. Despite this distinction, modern 
molecular techniques are showing that this division is somewhat superficial, given the 
similarity in their underlying causes. 
The phenotypic heterogeneity of these conditions can be attributed to the fact that 
these mutations occur in crucial genes and therefore have drastic effects on bone and 
cartilage growth. It is possible for mutations in the same gene to have slightly different 
effects, which could be interpreted clinically as different conditions. Additionally, 
mutations in the same molecular pathway, though in different genes, can have remarkably 
similar clinical presentations. Many of these disorders have unknown causes, although 
the rate of disease gene discovery has grown substantially due to next-generation 
sequencing (NGS) technologies.  
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 Individually, skeletal dysplasias are extremely rare with reported prevalence rates 
usually less than one in 10,000 births
3
 However, as a collective group they are more 
common, with studies finding occurrence to be around two in 10,000 births causing as 
much as 9.1 in 1,000 perinatal deaths
3, 4
. However, it is assumed that these figures under-
represent the true occurrence, which is estimated to be nearly four in 10,000 births
3
. The 
four most prevalent bone dysplasias are reviewed in Table 1. 
The skeletal dysplasias are usually caused by monogenic, Mendelian inheritance 
of deleterious mutations
5
. These disorders comprise widely ranging phenotypes and 
severities due to mutation heterogeneity in many underlying disease genes. These 
congenital skeletal dysplasias are usually inherited as autosomal recessive(AR), 
autosomal dominant(AD), X-linked recessive or dominant, with few being caused by 
gross chromosomal abnormalities, gene imprinting errors, and autosomal mosaicism
6
. As 
with any congenital defect, it is also possible for isolated dysplasias to be caused by 
environmental agents introduced to the fetus via the mother (see Environmental Effects 
on Vertebral Column Development on Page 18). The majority of skeletal dysplasias, 
however, are caused by AR or AD inheritance from apparently unaffected parents. 
Symptoms range from early onset arthritis in otherwise normal individuals to perinatal 
lethality, although disproportionate short stature is the most common presentation. This 
short stature is almost always due to abnormal long bone development. Defects in long 
bone development can create shortened, weak, or bowed limbs that result in short stature. 
Abnormal bone growth can also affect other body systems, commonly leading to 
neurological deficits and compromised organ function. The heterogeneity within the  
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Table 1. Most Prevalent Skeletal Dysplasias. The skeletal dysplasias exhibit highly 
variable incidence, symptoms and genetic variability.  
Condition Inheritance
1 
Incidence in 
births/10,000
7
* 
Common symptoms Associated 
Gene(s)
1 
Thanatophoric 
dyspasia 
AD 0.09-0.78 
extremely short 
limbs, pterygium on  
arms and legs, 
narrow chest, short 
ribs, hypoplastic 
lungs, and enlarged 
head with a large 
forehead and 
marked 
hypertelorism 
FGFR3 
Osteogenesis 
imperfecta 
AD and AR 0.36-2.2 
Brittle/easily 
fractured bone, 
scoliosis, joint 
laxity, discolored 
sclera, bone 
deformity, short 
stature 
COL1A1, 
COL1A2, 
IFITM5, 
SERPINF1, 
CRTAP, 
LEPRE1 
Achondroplasia AD 0.13-1.04 
Disproportionate 
short stature, spinal 
growth 
abnormalities, 
bowed legs, 
hydrocephalus 
FGFR3 
Achondrogenesis AD and AR 0.03-0.64 
Poor to no 
ossification of 
cartilage, leading to 
poor or no bone 
formation, short 
limbs and ribs, 
narrow chest, easily 
fractured bones, 
weak skull bones 
SLC26A2, 
COL2A1 
TRIP11 
*Incidence ranges gathered from multiple studies with varying degrees of 
ascertainment bias 
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skeletal dysplasias, as well as between individuals with the same condition, complicates 
the ability of physicians to accurately diagnose these patients. 
Skeletal dysostoses are rarely observed, occurring at such low incidence levels 
that no comprehensive study has ascertained their frequency. As stated earlier, skeletal 
dysostoses are those conditions in which a single bone or bone group is affected. The 
effects range from mild growth inhibition to complete absence of entire bone groups. The 
axial skeleton is most often involved in skeletal dysostoses with common symptoms 
including poorly formed cranial bones, mandible, ribs and vertebrae. The malformation 
or absence of these axial bones results in a heterogeneous sequela that can include 
malformation of associated body systems, including pulmonary restriction, genital and 
anal defects, and spina bifida
8
. 
. Diagnostic features of spondylocostal dysostosis include mild scoliosis, 
involvement of more than ten vertebrae, absence of vertebral fusions; malformed ribs 
with symmetrical chest shape, and a characteristic “pebble beach” appearance in 
adolescent radiographs
9
. Skeletal dysostoses appear to affect both sexes equally and most 
are AR although there are instances of AD inheritance
9
. Severe forms lead to conditions 
such as Jarcho-Levin Syndrome, which is more accurately designated either 
spondylothoracic or spondylocostal dysostosis
1
There are currently only five genes known 
to cause spondylocostal dysostosis: DLL3, MESP2, LNFG, and HES7
9, 10
. All of these 
genes are involved in the Notch signaling pathway, which creates and maintains protein 
gradients that determine basic body patterning and segmentation
1, 8, 11
. The Notch 
pathway is critical in cell-to-cell signaling. The pathway ultimately controls the 
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expression of many genes needed for embryogenesis and for continuing survival 
throughout life 
11
 However, embryologic mouse studies have shown that the causative 
genes of spondylocostal dysostosis are involved only in vertebral segmentation and have 
no other known functions past early embryo development 
11
.  
Diagnosis of skeletal dysplasias and dysostoses is accomplished through a 
multidisciplinary approach, requiring family history, physical examination, and 
radiographic images, possibly followed by molecular and genetic testing
2
.  
One of the simplest, most informative pieces of information for diagnosis is an 
accurate family history. This should include all affected family members and note the 
possibility of consanguineous relationships either in the family’s distant past or more 
recently 
2
. As these are genetic diseases, consanguinity between parents significantly 
raises the possibility of having affected offspring. Some skeletal dysplasias have been 
associated with increased paternal age, so it may also be important to note ages of family 
members at time of proband conception
7
.  
Physical examination allows for detailed anthropometric measurements of 
upper/lower body segment ratio, sitting height, and arm span as determinants of short 
stature
2
. During the exam, the physician can also look for concomitant phenotypic 
markers found in skeletal dysplasias, such as large cranium, disproportionate facial 
features, syndactyly, and bowed limbs.  
Radiographic images are currently the most accepted method for diagnosing 
skeletal dysplasias and dysostoses. Study of the images focuses on the skull, entire spine, 
pelvis and extremities, with particular detail put on the hands and feet 
2
. Additional aids 
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in diagnosis include CT and MRI scans, and detailed radiographs taken before epiphyseal 
growth plate closure during puberty
2
. Study of epiphyseal growth plates, via radiographic 
imaging or bone biopsy, allows a view into how the bone is growing and can demonstrate 
at exactly what stage or even what cells are defective
2
.  
Approximately 100 of the over 350 skeletal dysplasias and dysostoses have 
apparent diagnostic features in the antenatal period, allowing detection as early as 14 
weeks utilizing ultrasound
6
. This also means that diagnosis for two-thirds of skeletal 
dysplasias does not occur until mid to late childhood, complicating medical management 
of these children and delaying reproductive counseling for the parents. In one study, 
technicians were able to correctly detect 98.8% of all skeletal dysplasias delivered at a 
medical center
12
. The most important indications of skeletal dysplasia in utero are 
abnormal bone length ratios, facial anomalies detected by three-dimensional ultrasound, 
and chest to abdomen width ratio
6
. The addition of three-dimensional ultrasound 
technology promises to raise the detection rates higher, while decreasing the rate of false 
positives. Even with the radiographic evidence, definitive diagnosis is usually established 
by pre-natal molecular analysis, which entails invasive procedures that may or not prove 
beneficial to infant survival
7
. The increased use of ultrasonography to detect skeletal 
dysplasias has also led to increasing numbers of pregnancy terminations when a disorder 
is suspected, which has put even greater importance on molecular and genomic analysis 
for diagnosis and appropriate genetic counseling
7
. Even with all this information, 16-42% 
of skeletal dysplasia cases do not fit into specific diagnostic categories
7
.  
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Treatment for these disorders is mostly limited to palliative care and surgery. The 
variability in individuals with these conditions necessitates a case-by-case treatment after 
extensive observation and interdisciplinary collaboration. Common treatments for this 
group of disorders include foramenotomy to alleviate spinal cord compression, joint 
replacement, osteotomies to correct structural abnormalities in bones, and spinal fusions 
or growth rods
2, 13
. 
Although treatments are limited for these patients, biomedical research has helped 
identify the underlying cause of many of these disorders. These advances are made all the 
more important given how much can be learned about bone and cartilage biology. The 
skeletal dysplasias provide opportunities by physician-researchers to better understand 
the basic underpinnings of how cartilage and bones grow, differentiate, and mature. The 
knowledge gained by the study of these conditions has the promise to provide better 
insight and possible treatments for common conditions such as arthritis and 
osteoporosis
14
.  
Bone Growth and Development 
With the important function of bone in normal vertebrate development, the 
precursor cells and structures of bone are already partially formed by the end of the first 
month following conception. Bones serve as a support for the body, allow movement, 
protect vital organs, and serve as reserve for important cell types and inorganic minerals. 
The adult human skeleton consists of 206 bones: 126 appendicular, 74 axial, and 6 
ossicles. Axial bones are vertebrae, sacrum, ribs, and some regions of the cranium. 
 8 
 
Appendicular bones are all bones that are not axial, which include all the bones of the 
arms and legs. Ossicles are the bones in the middle ear that make hearing possible.  
The initial development of the skeleton is controlled by highly conserved, 
complex signaling pathways that determine cell differentiation, proliferation, apoptosis 
and basic body patterning as seen in Figure 1. The vertebrate skeleton has a highly 
variable embryological and developmental origin.  
 
 
 
 
 
 
 
 
 
Figure 1: Complex Cell and Pathway Regulation. Signaling pathways control body 
segmentation and growth in the appropriate rostral-caudal, dorsal-ventral, left-
right orientation (Figure taken Olsen et.al. 2010) 
All bones are derived from mesenchymal tissue which further differentiates into  
either ectodermal or mesodermal tissue. The craniofacial bones are derived from neural 
crest cells, while the axial skeleton and appendicular bones are derived from 
paraxial(somites) and lateral plate mesoderm, respectively
15
. These cells follow the 
prescribed developmental patterns and locate to sites of future bone growth. Once in the 
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correct location, these cells undergo condensation and proliferation to form the outlines 
of future bone structures. Bone is formed by one of two processes: intramembranous or 
endochondral ossification.  
Intramembranous ossification occurs in the flat bones of the skull, most of the 
mandible, clavicle and sub-periosteal bone shaft of long bones
16
. This process results in 
the direct differentiation of condensed mesenchymal tissue into osteoid secreting 
osteoblast cells. The osteoid is comprised of proteoglycans and type I collagen fibers. 
The osteoblast cells then begin to secrete alkaline phosphatase which encourages 
mineralization of the osteoid by precipitating out of solution inorganic calcium phosphate 
salts, such as hydroxyapatite. During this process, osteoblast cells form islands of 
ossification, which slowly grow and fuse into a single bone. The osteoblast cells become 
surrounded by the bone growing around them and become cemented into small areas 
called lacunae. At this point, the cells are called osteocytes, are completely avascular, but 
maintain cellular signaling to one another through a web of interconnected cellular 
membrane extensions called canaliculi. This process continues until the initial layer of 
bone is surrounded by two layers of compact bone with the spongy bone in the middle. 
Most bones however are produced by endochondral ossification. This process 
occurs in the long bones, vertebral column, ribs, and pelvis
17
. Endochondral ossification 
is differentiated from intramembranous in that it first requires a cartilage template before 
ossification can begin
18
. Undifferentiated mesenchymal tissue begins to condense and 
fuse into a continuous outline of the future bone
16
. The eventual size of the cartilage 
model (anlage) is determined by the size of the initial size of the mesenchymal 
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condensation island. The condensed mesenchymal cells then undergo further 
differentiation into chondroblasts and begin secreting an extracellular matrix comprised 
mostly of type II, IX, XI collagen and aggrecan
17, 19
. The hyaline cartilage model, as seen 
in the first stage of Figure 2, is the result of appositional and interstitial chondroblast 
growth and secretion. When fully formed , the anlage is relatively the same size and 
shape of the future bone. Similar to the fate of osteoblasts in ossification, chondroblasts 
are sealed into lacunae and become chondrocytes. During the next step, chondrocytes 
begin to hypertrophy and secrete type X collagen, followed by promotion 
of cartilage biomineralization and apoptosis. Chondrocytes undergoing cell death 
promote both blood vessel invasion of the anlage by secreting vascular endothelial 
growth factor and degradation of the mineralized cartilage by matrix 
metalloproteinases
17
. This center of vascularization and cartilage degradation is the  
 
Figure 2: Process of endochondral ossification. The different stages of endochondral 
ossification are shown starting on the left, maturing towards the right. (Figure 
taken OpenStax College 2013).  
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primary ossification center seen in stage 3 of Figure 2. The introduction of blood vessels 
to the region brings osteoprogenitor cells, which differentiate into osteoblasts. 
Osteoblasts then begin the process of ossification in the same manner described for 
intramembranous ossification. This process progresses up and down the bone until it 
reaches the epiphysis, at which point a layer of active cartilage becomes trapped between 
the primary and secondary ossification centers (stage 5 of Figure 2). This creates the 
epiphyseal growth plate which will allow for longitudinal growth during adolescence and 
puberty. The resting zone of the epiphyseal growth plate is comprised of chondrocyte 
specific stem cell that can create more cells like it or differentiate into cells of the 
proliferative zone. The cells in the proliferative zone are true chondrocytes that are  
 
Figure 3: Zones of Epiphyseal Plate. Signaling molecules control the complex task of 
endochondral ossification seen at the epiphyseal plate. At the epiphysis of long bones, all 
stages of ossification can be viewed. (Figure taken Michigami et.al. 2013). 
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 (comprised of multiple collagens, aggrecan, hyaluronin, and other structural proteins) is 
directed to continually undergo cell cycling in order to make more chondrocytes. It is at 
the proliferative zone that the cells organize into columnar structures that will continue to 
be seen in the following zones. In the hypertrophy zone, the cells grow mainly in size to 
support the increased extracellular matrix secretions. Once the extracellular matrix 
formed, it begins to calcify. This calcification process leads to the apoptotic death of the 
chondrocytes and eventual conversion of the extracellular matrix from cartilage into 
endochondral bone. In the absence of the chondrocytes, blood vessels bring 
osteoprogenitor cells, osteoclasts, and the first bone marrow cells. As in intramembranous 
ossification, matrix metalloproteinases and osteoclasts break down the mineralized 
cartilage, while the osteoprogenitor cells proliferate and differentiate into the bone 
building osteoblasts and bone marrow cells. The continual process of chondrocyte stem 
cells differentiation, growth, and calcification forming a scaffold for bone deposition is 
how bones grow in length and width.  
 
Development of the Vertebral Column  
The preceding explanation is the classical, textbook case of endochondral 
ossification. The irregular bones, namely the vertebrae, have modified patterns of 
endochondral ossification in order to form these irregularly shaped bones.  
The human vertebral column is made up of 7 cervical vertebrae, 12 thoracic 
vertebrae, 5 lumbar vertebrae, as well as 5 fused vertebrae that form the sacrum and four  
coccygeal vertebrae (Figure 4A). The function of the vertebrae is twofold: to carry the  
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Human Vertebral Column. (A.)The three main regions of the vertebral 
column are the cervical, thoracic and lumbar. The size and number of vertebrae are 
determined early in embryonic development through complex pathways and signaling 
gradients. Aberrant signaling can cause common congenital spinal abnormalities 
including hemi-vertebrae, block vertebrae, scoliosis, and osteoporosis (Figure taken Seer 
Training: Axial Skeleton) (B.) The anatomy of the vertebra is comprised of several 
processes that coalesce around the embryonic spinal cord (Figure taken Anatomy and 
Physiology). 
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weight of the body and to envelop the vitally important spinal cord for protection from 
injury (Figure 4B). The complex structure of the vertebrae forms by several centers of 
chondrogenesis surrounding the spinal cord and subsequently undergoing endochondral 
ossification. In addition to the skeletal aspect of the vertebral column, intervertebral discs  
segment individual vertebrae and allow for the range of motion and even weight 
distribution throughout the column.  
Although growing concurrently in the same limited body space, skeletal and 
neural elements of the vertebral column develop independently from one another. 
Therefore, it is possible to form a complete central nervous system without forming the 
skeletal support structure necessary for life. The origins of the skeletal structures arise  
very early in embryogenesis, during a process called gastrulation. Gastrulation takes the 
embryo from the bilaminar disc stage of development to the trilaminar stage. The three 
cell layers at this point are the endoderm, mesoderm, and ectoderm.  
Differentiation of the nervous system occurs before the processes that lead to 
bone development. The notochord, the initiating structure for neural development, is also 
required for proper vertebral column development. The notochord, as seen in Figure 4A, 
induces the formation of the neural groove, which folds in on itself to form the neural 
tube by the fourth embryonic week
23
. The neural tube then goes on to development into 
the brain, spinal cord, peripheral nerve afferents and preganglionic fibers of the 
autonomic nervous system
23
.  
The mesoderm that will become the vertebrae differentiates into paraxial 
mesoderm. Several important signaling pathways control the migration and formation of 
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mesodermal cells. The importance of these pathways, namely the T-box transcription 
factors, WNT, NOTCH, and SMAD pathways are integrally involved in the very early 
stages of vertebral development
24
. Regulatory genes that control cell metabolism, namely 
those involved in retinoic acid catabolism, also impact vertebral column growth
24
. 
Catabolic enzymes are necessary in proper vertebral development by keeping retinoic 
acid and other metabolic by-products levels at a minimum
24
.  
Paraxial mesoderm will undergo hypertrophy and condense into structures called 
somites (see Figure 5). One accepted theory for somitogenesis is described as a ‘clock 
and wavefront’ model, which describes the rostral to caudal development of somites25. 
The model posits that biochemical and protein gradients, set up by and maintained by 
crucial signaling pathways, direct this differentiation in a wave-like pattern. The idea is 
that the crest of the wave brings rapid differentiation followed by a slower formation of 
the somite structure. If this wave is in any way interrupted or altered, congenital vertebral 
malformations can occur
13
. By the time the somites can be recognized by microscopy, all 
necessary cell programming has occurred for the cells to continue on to form vertebra, 
ribs, and cranial bones
23
. The first somites can be detected just before the fourth 
embryonic week of human development (Figure 5A). 
Seeing that somites develop into a wide range of tissues, the underlying patterns 
of differentiation are complex (Figure 5C). At the earliest stage, the somite is a hollow 
sphere formed by pseudostratified epithelium around a hollow space. This space is then 
invaded and filled by mesenchymal cells in the following developmental event
23
. The 
somites undergo segmentation to form independent units and line up in pairs on either  
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Figure 5: 
Coronal and 
transverse 
overview of 
vertebrae 
development. 
Differentiation 
of the vertebral 
elements is 
illustrated. The 
greyed regions 
seen in (D.) and 
(E.) denote the 
schlerotomal 
regions that will 
become vertebral 
body, neural 
arch, rib anlage, 
and 
intervertebral 
disc (Figure 
taken Lovell 
et.al. 2006)  
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side of the embryonic midline
26
. Segmentation begins mid-spine and continues both 
rostrally and caudally along the spinal process
26
. The sclerotome, the medioventral region 
of the somite, goes on to form the vertebral bodies and arches that surround the neuronal 
tissue that comprises the spinal cord
23
. 
Remaining parts of the somite are called the dermatome and myotome, which 
differentiate to become intervertebral discs, ribs, dermis, muscle, and tendons (Figure 5). 
This process creates the individual vertebrae and segmented units in the vertebral 
column. Interruption of somitogenesis results in fused, hemi-, wedge, or absent vertebrae. 
 
Environmental Effects on Vertebral Column Development 
 Even with modern genetics and genomics techniques, many cases of vertebral 
malformations are unclassified with no known cause. Although genes can play a large 
role in disease etiology, environmental factors also have important actions on 
embryological growth and development.  
 For example, maternal exposures to various drugs and chemicals have been 
associated, both observationally and in animal experiments, with congenital vertebral 
malformations. Alcohol, anticonvulsants, anti-arrhythmia medications, fungal toxins, 
hyperthermia, carbon monoxide, anoxia, retinoic acid, maternal insulin-dependent 
diabetes mellitus and gestational diabetes have all been shown to influence vertebral 
development
13
. Accidental exposures to drugs, toxins, and chemical waste have been 
implicated in birth defects affecting animal models
13
.  
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 Diabetes, one of the most common diseases in developed countries, is also a 
possible factor in developing vertebral defects
24
. For instance, caudal regression 
syndrome, a condition in which the sacral, lumbar, and lower thoracic vertebrae are 
absent, is associated with maternal diabetes in 16% of cases
24
.Several mechanisms of 
action have been proposed to help explain the link between maternal diabetes and 
congenital vertebral malformations. One proposal suggests that the increase in reactive 
oxygen species produced by diabetic mothers alters somitogenesis
27
. However, diabetes 
alone cannot be the cause of all vertebral defects, given the number of infants born to 
diabetic mothers every year.  
 Another common cause of congenital defect is physical interruption or injury to 
the fetus while in utero. For example, too much or too little amniotic fluid, called 
polyhydramnios and oligohydramnios respectively, can lead to gross malformations of 
limbs and cranium. Polyhydramnios and oligohydramnios are usually secondary 
conditions due to maternal environment and fetal congenital anomalies affecting the 
gastrointestinal and renal systems. Localized vascular hypoperfusion, caused by amniotic 
bands or idiopathic reasons, can cause congenital amputations and malformations
24
. 
 Different variables in maternal environment contribute in varying degrees to the 
formation of vertebral defects
13
. As with most phenotypic variation, there is a complex 
interplay between genotype and environmental effects that affects the phenotypic 
outcome. 
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Review of inheritance and genetic variation 
 There are 226 genes that when mutated are known to cause skeletal dysplasias or 
dysostoses
1
. In order to better explain the underlying causes of these conditions and the 
various genomic strategies necessary for investigating them, a basic review of simple 
Mendelian inheritance and genetic mutations is needed.  
 There are many ways in which genetic information can be passed down to the 
following generation, but we will focus on the three basic Mendelian inheritance models 
that apply to this study.  
AD inheritance occurs when only one copy of a disease-causing gene is necessary 
to manifest the disease. In this simple case, one of the parents must also be affected in 
order to pass on the mutant allele. Penetrance of this disease into each generation can be 
high or low, and affects both males and females equally (Figure 6). 
AR inheritance requires two copies of the disease-causing gene to be present in 
the offspring for the disease to occur. The three possible parent pairings that would create 
this event are: both parents are affected AR, one of parents is affected AR and the other 
parent is an unaffected carrier, or both parents are unaffected carriers. Most commonly, 
offspring affected by AR diseases are produced by the pairing of two unaffected carriers 
(Figure 6). These parents do not know they have a deleterious mutation because they still 
have one functional allele. The deleterious allele circulates in the population at very low 
levels (assuming Hardy-Weinberg Equilibrium, the rate would be equal to p
2 
+ 2pq + 
q
2
=1), meaning that very few instances of the disease occur. However, unions between 
related individuals results in an increased probability of rare, recessive diseases in the 
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offspring. A consanguineous union increases the chance of producing affected offspring 
since the parents will share random deleterious mutations from their common ancestry. 
AR inheritance affects males and females equally. 
X-linked diseases occur due to sex determination system operating in humans. 
Male gender is determined by an XY genotype, while female gender is determined by an 
XX genotype. X-linked diseases occur when deleterious variation occurs on a 
chromosomal or genetic level on the X chromosome. X-linked diseases occur much more 
commonly in males due to the fact that males have only one X-chromosome, while 
females have two. Only one deleterious mutation is needed to affect a male, whereas two 
are needed to produce an affected female. One rare mutation will occur more commonly 
than two in the same individual, thus explaining why males are affected 
disproportionately. Confounding the idea of simple Mendelian inheritance is the 
occurrence of de novo mutations. This type of mutation is not found in either parent, but 
in the germline of a single parent that results in an affected offspring. Errors during 
gametogenesis can create novel disease-causing mutations. In these cases, no evidence of 
the disease is seen in the family history and genetic testing will show that the parents are 
not carriers for the disease (Figure 6). De novo mutation is always suspected when the 
disease occurs spontaneously in a family and is usually the result of a dominant mutation.  
Genetic mutations can be passed on in different ways, as well as in different 
forms. At the genomic scale are gross chromosomal abnormalities. This type of variant 
occurs due to changes to chromosomal structure as a result of aberrant meiosis events. 
These events result in large deletions, translocations, and trisomies. Conventional 
 21 
 
karyotyping can detect these errors by simple microscopy, with a resolution limit of 5 
Mb. On a slightly smaller scale, copy number variants (CNV) occur when segments of a 
chromosome are duplicated or deleted on the order of 1 kb to several Mb. The definitive 
cause of CNVs is not well understood, but DNA replication and repair errors are 
suspected. CNVs are present in every individual, but how CNVs cause disease or their 
impact on health is still being investigated. Also caused by errors during DNA replication 
are insertion-deletion variants (indels). These variants are defined at the genetic level, 
 
Figure 6: Inheritance patterns dictate data analysis approach. When beginning a new 
investigation, one may or may not know the inheritance pattern of the disease in question. 
Knowing this information can be used to narrow down the search for candidate genes. 
Mosaic mutations are not covered in this review due to their rarity in genetic diseases, 
although these types of mutations are involved in tumorigenesis. (Figure taken Boycott 
et.al. 2013) 
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encompassing multiple or single insertion or deletion events. An example of an indel 
would be ATGC-TGC where the – denotes the deletion of a base so that an eight 
nucleotide sequence becomes only seven nucleotides long. This type of variation can 
cause a frame shift resulting in the introduction of early stop codons or intron splicing 
errors in the mRNA and resulting protein product. Single Nucleotide Polymorphims 
(SNP) are yet another type of variant introduced due to replication error. SNP variants are 
defined as the incorporation of an incorrect base that differs from the template which the 
new DNA strand is being produced. Using the same sequence as above, an example of a 
SNP would result in the sequence changing to ATGCATGA where the last nucleotide has 
changed from a cytosine to an adenine base. SNPs can have deleterious effects by 
changing amino acid sequences within proteins, introducing or eliminating stop codons, 
or causing splice-site errors. Aside from chromosomal abnormalities, which can be 
detected by high-density SNP arrays the above described genetic variation can be 
detected through sequencing techniques.  
 
Next-generation sequencing 
 The term NGS has come to represent any sequencing technology developed after 
Sanger sequencing was introduced in 1997 by Frederick Sanger. First generation 
sequencing machines utilized the Sanger sequencing method, but added automation and 
speed to the process. The advancement that allowed the automation and speed was the 
development of fluorescent dyes which replaced the use of radioactive markers and 
radiography. Following gel slab electrophoresis, capillary electrophoresis further allowed 
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low cost, high efficiency, and low false-call rates. Capillary electrophoresis remains the 
gold standard in clinical and forensics laboratories today. The major drawback of 
capillary electrophoresis is that sequences are produced too slowly for modern demand 
due to the limited number of detection sensors ( < 96) and limitation on sequence read 
length ( < 1000 bp). As demand for genetic sequences has increased, other technologies 
have been developed to meet the need for high throughput sequencing machines. Most, if 
not all, of these new technologies rely extensively on the groundwork done by earlier 
sequencing efforts, namely the Human Genome Project.  
All NGS instruments have a few aspects in common. Before any sequencing 
occurs, a critical step shared by all NGS methods is library preparation, in which the 
DNA is fragmented, enzymatically cut for end polishing, and ligated to adaptor 
nucleotide sequences (Figure 7a). These adaptor sequences allow for the fragmented 
DNA to be bound to solid surfaces of silicon beads or chips on which the sequencing 
reactions will take place. Using various technologies, NGS instruments rely on massively 
parallel sequencing reactions to create millions of short reads that are then aligned to each 
other based on overlapping sequences (shotgun sequencing) or to previously created 
reference genomes. Variants are then called based on dissimilarity of the collected data to 
the reference. At this point in time, third generation sequencers are available with the 
goal of making genomic research available to smaller laboratories and the clinical 
diagnostic market. 
Illumina® has dominated the high-throughput sequencing market in sales and 
number of associated publications with its Genome Analyzer and Hiseq2000. 
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Additionally, Illumina® now has a bench-top low-throughput, fast turnaround machine 
called the Miseq
29
. The sequencing approach taken by these and other instruments is 
called sequencing-by-synthesis. Sequencing-by-synthesis (Figure 7c) is achieved by  
 
 
Figure 7: Sequencing-by-synthesis steps. (a.) Library preparation involves 
fragmentation, enzyme degradation, and adaptor ligation (b.) Adaptor-ligated fragments 
are fixed to a silicon flow cell where the sequence amplification and signal detection 
occurs. (c.) Molecular view of sequencing-by-synthesis including fluorescent dye 
cleavage which creates the fluorescent signal when a labeled nucleotide is added to the 
growing strand (Figure taken Mardis 2013) 
 
utilizing fluorescently labeled reversible-terminator nucleotides on clonally amplified 
DNA templates, which are bound to the acrylamide coating of a glass flow-cell
29
. 
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Following this step, bridge amplification (Figure 7B) occurs in order to form clusters of 
clonal DNA fragments
31
. The library is then cut into single strands by linearizing 
enzyme, at which point dideoxy-nucleotides are added to the reaction
31
. These 
nucleotides are fluorescently labeled so that incorporation into the growing strand results 
in a fluorescent signal that is detected in real-time by a charge-coupled detection cell
31
. 
This technology produces reads with 98-99% accuracy with a run time of several days 
(only hours in the Miseq), with typically the lowest cost per base
31
. 
Emulsion polymerase chain reaction (PCR) is a technique which is utilized to 
amplify DNA sequences so that NGS instruments can detect the sequencing reactions 
occurring. This method is utilized in Roche® 454™, Life Technologies® SOLiD™, and 
Ion Torrent® PGM™ and Proton™ sequencers. This reaction takes place with PCR 
reagents and template DNA contained within a single oil micelle. Primers are then added 
to these micelles which are subsequently moved into individual cells or wells in which 
the sequencing reactions will take place. 
The Ion Torrent® PGM™ and Proton™ sequencers are unique in that the 
instruments rely on detecting minute changes in pH, rather than fluorescent signals. A 
graphical representation of the technology is depicted in Figure 8. First, the DNA must be 
prepared into a library via fragmentation, enzymatic end polishing and adaptor ligation
31
. 
Amplification of template DNA occurs via emulsion PCR and sequencing occurs on an 
Ion Torrent® Ion Chip™. The Ion Chip is a specially designed silicon chip which is able 
to detect minute pH changes that occur when the polymerase adds nucleotides to the 
growing progression of the ongoing PCR
32
. Due to the lack of fluorescent labeling, 
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washes of single dNTPs (either A,G,C, or T) are added through progressive washes so 
that the instrument recognizes which dNTP was added and whether wells reacted to 
produce a change in pH. Sequence information is gained one base addition at a time, 
although nucleotide washes and polymerization occur simultaneously in massively 
parallel sequencing reactions. Homopolymers (ie: GGGGG) are detected as a larger pH 
change, which the instrument detects and attributes several nucleotide additions based on  
 
  
Figure 8: Ion Torrent® sequencing technology. (a.) The template DNA is ligated to 
adaptor embedded in small beads. (b.) The addition of new nucleotides to the 
complementary strand of the template DNA creates hydrogen molecules, lowering the pH 
in the microfluidic cell which is then detected by the instrument (Figure taken Mardis 
2013).  
 
 
the signal from single nucleotide additions. The Ion Chip has difficulty detecting these 
homopolymers, resulting in higher error rates that other NGS instruments, leading to 
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higher false call rates. Ion Torrent® has accounted for these errors by producing as many 
reads as possible for each position sequenced, as well as by removing known indels at the 
data analysis stage following sequencing. Despite these corrections, Ion Torrent® has the 
highest rate of indel false-positive calls compared to other third-generation sequencers
31
. 
Where this technology is most powerful is in the amount of data that can be generated on 
the scale of hours as opposed to days. Additionally, Ion Torrent® instruments have a 
substitution false-call rate slightly lower than than Illumina®, a higher true positive rate, 
and longer average read lengths
29,31
. 
 
Exome sequencing  
The goal of many researchers is to obtain genomic information at an affordable 
cost and to integrate those instruments and information into clinical diagnostics.  
A cost-effective method of sequencing the most relevant genomic information is 
exome sequencing. There are approximately 20,000 genes in the human genome, all of 
which contain intronic and exonic regions. During and following transcription, introns 
are spliced out of pre-mRNA molecules as part of the processing that takes place to form 
mature mRNA. Exons constitute barely 1.5% of the genome, but have the most obvious 
impact in causing disease states. This is due to the fact that the genetic information to 
create proteins is found only with exonic sequences. Mutations within exonic regions can 
affect protein folding, which can affect protein function. Many times these are loss of 
function mutations which decrease the activity or expression of the protein. However, 
pathogenic mutations can also cause new functions or aberrant expression in incorrect 
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tissues or at incorrect developmental periods. Generally, mutations within introns will not 
be expressed in the encoded proteins and are therefore likely not pathogenic. The one 
exception is in splice-site mutations, which can cause aberrant splicing of pre-mRNA. 
This type of mutation can cause truncated or elongated transcripts by inclusion or 
exclusion of genetic material, which usually results in early translation termination that 
can result in non-functional proteins or low protein expression levels.  
Exome sequencing focuses only on these exonic regions. Multiple sequencing 
instruments support exome sequencing capabilities. Targeting only the exome acts as a 
powerful data filter to get directly at the most high value genetic information. The exome 
is targeted by creating sequence libraries via multiplexed PCR using designed 
oligonucleotide primer pairs to amplify the vast majority of known exons. By doing so, 
whole exome data can be generated for several individuals in a fraction of the time and 
cost that it would take to carry out just one whole genome sequence. For example, Life 
Technologies’™ Ion Ampliseq™ exome kit utilizes over 294,000 primer pairs to capture 
as much as 97% of the total exome. 
Exome sequencing has been moving to replace traditional means of identifying 
disease causing candidate genes. In the past, candidate loci were identified using linkage 
analysis and association studies. These types of studies require substantial time and 
investment, as well as a large number of affected individuals, whereas exome sequencing 
studies can be completed within weeks to months studying as few as a single affected 
patient. Traditional methods combined the results of several types of positional mapping 
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Figure 9: Impact of exome sequencing on rare genetic disease gene discovery: The 
pace of discovery of novel disease genes has grown greatly since the application of whole 
exome sequencing to rare Mendelian disease-gene discovery was introduced in 2011. 
(Figure taken Boycott et.al. 2013) 
 
analysis to narrow down the region of interest so that sequencing could be employed. 
This approach, however, is easily confounded by diseases with multiple phenotypes 
caused by more than a single gene
33
. The impact of exome sequencing is apparent given 
that identification of novel pathogenic genes has grown from a few per year to over 70 
since the introduction of exome sequencing to the field (Figure 9). 
 
Generation of Genetic Variant Data 
The data that the next generation sequencers produce is in the form of millions of 
short sequence strings called reads. There are multiple reads per genome position, which 
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defines the depth of coverage for each nucleotide base position. Attached to every 
nucleotide sequence generated is a quality score. This is called a Phred quality score, 
which is a calculated probability of the accuracy of the nucleotide base generated by the 
sequencing instrument. The Phred quality score is defined by a logarithmic equation so 
that a Phred score of 10 denotes a 1 in 10 probability of a false call, which is equivalent 
to saying that the probability that the nucleotide was correctly called is 90%. Due to the 
logarithmic function, a Phred score of 20 represents a 99% base call accuracy, and a 
score of 30 equates to a 99.9% base call accuracy estimation. The read sequences and 
accompanying quality scores are written into a text file with the extension ‘.fastq’. From 
here, the .fastq file can be compared to a reference genome or subjected to quality score 
analysis. 
For most applications, the next analysis step is sequence alignment. The .fastq file 
is input into sequence alignment programs which compare the reads found in the file to a 
specified reference genome. These reference genomes are complete genomes that were 
first created using the shotgun Sanger sequencing approach and are now supplemented 
with NGS data. Currently, the most used human reference genome is called GRCh37 by 
the National Center for Biotechnology Information, but is most often seen referred to 
simply as hg19, as annotated by the University of California, Santa Cruz Genome 
Browser. By comparing the sequence of each read to the sequence in the reference 
genome, computer software can determine where that read fits into the reference genome. 
This process is called mapping or read mapping. The probability that the read has been 
mapped to the correct location is also represented by a Phred quality score. Once this 
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alignment is complete, the computer software output is a binary alignment mapping file 
with the ‘.bam’ file extension. These files contain both mapped and unmapped sequences 
aligned to the human genome. Sequence alignment programs can be integrated into the 
proprietary NGS pipeline software sold with the instrument, however many labs use 
alternative programs developed by other researchers or by in-house bioinformatics staff. 
 
 
Figure 10: Marked 
Difference in Variant 
Callers. Looking at the 
same exome, different 
programs have varying 
results. Each numerical 
notation demonstrates 
the shared SNP number 
and shared indel 
number of the 
respective overlapping 
region (Figure taken 
Pabinger et.al. 2013) 
 
 
Once sequences are aligned to the reference genome, variant calling programs 
look for sequence variation, such as the proprietary Life Technologies’™ Ion Reporter™ 
or freely available programs like GATK
34, 35, 36
. When the software finds a non-reference 
nucleotide base call, that variant is flagged and put into a list of variants that the variant 
calling program compiles as it searches through the entire exome. The results of this 
search are compiled in a .vcf file. Variant calling programs vary widely on the number 
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and type of variants detected (Figure 10). Generally, there is better concordance between 
variant callers on single nucleotide variants, and greater variation concerning indel 
variations
37
. GATK
34,35,36
, one of the most widely used variant callers, is more sensitive 
than most other programs, but is less specific. It is important to make the distinction that 
sensitivity reflects the sheer number of called variants, while specificity focuses on the 
ability to correctly detect true variants. The ideal variant caller would be one that is both 
100% sensitive and 100% specific, although currently available programs attempt to find 
a balance between this tradeoff. Pabinger et.al. 2013 provides a thorough review of 
variant callers. 
The final step in preparing data before any analysis takes place is variant 
annotation. Variant annotation describes the process of collecting as much data available 
about that variant in particular. Several variant caller programs, as well as independent 
programs, gather data from public databases and organize all the information into a single 
file. Annotated data include the mutation region (exonic, intronic, intergenic, etc.), 
zygosity based on variant frequency (homozygous, heterozygous), if the variant is found 
in public databases, whether it occurs in an evolutionarily conserved region, as well as 
probability-based estimations of the variant’s effects (damaging, benign, unknown).  
Many of these annotation categories require statistical algorithms. These 
algorithms assign scored values to each variant. Representative programs include SIFT
38
, 
Polyphen
39
, and MutationTaster
40
. Each of these programs access protein structure 
databases, sequence databases, phylogenetic databases, and variant databases to perform 
analyses. The purpose behind utilizing these databases is that pathogenic variants are 
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more likely to be found in crucial protein domains, in genetic regions conserved in 
related species, and will be novel. Mutations in critical protein domains will affect 
protein folding, which will in turn affect protein function. A lack of functional protein is 
a common cause of many genetic conditions. 
An example of these types of program, SIFT
38
 predicts whether a mutation will 
affect protein function. This prediction is based on the degree of conservation of the 
amino acid throughout sequences found in sequence databases. Based on the degree of 
conservation, SIFT will assign a score to the mutation. The scores are informative, but 
are by no means an absolute measure of the deleteriousness of a mutation. By themselves, 
these scores are meaningless. They are only informative in relation to other variant 
scores. Through many experiments across many different species, scores ranges have 
been adopted and assigned meaning. A mutation can be considered damaging if the score 
is in the ranges 0-.05. Scores ranging from .05-.1 are generally deemed possibly 
damaging. Any scores beyond these ranges are considered to be neutral mutations and 
therefore likely not causative of any genetic condition.  
The predictive scores, along with concrete information such as whether the 
variant is exonic and the zygosity of the variant, are compiled into a single annotated .vcf 
file which is then used to filter variants in order to find candidate alleles. 
 
Data filtering approaches  
Initially, the first consideration when designing filtering of variant datasets is the 
likely mode of inheritance. Extensive family histories of several unrelated affected 
 34 
 
individuals can answer this question. However, many times family histories are 
incomplete or unavailable. Additionally, family histories can be of limited use due to 
factors such as incomplete penetrance, phenotypic variability, de novo causative 
mutations, and limited number of affected individuals available for analysis. With no 
family history, an assumption must be made about the mode of inheritance and 
thoroughly investigated. If the data filtering for this model returns no candidate variants, 
then another inheritance model is explored in order of likelihood. Analyses begin with the 
most stringent criteria and are slowly relaxed until candidate variants are identified. 
Additionally, analyses first look for similarities between affected individuals until all 
options are exhausted, at which point each proband can be analyzed separately. Figure 11 
outlines the basic framework for variant data filtering. 
Identity-by-descent (IBD) filtering is a method of limiting the scope of variant 
analysis to specific genomic regions. IBD filtering, also called autozygosity mapping, 
reveals biallelic mutations in autosomal recessive genes
41
. This process is achieved by 
identifying runs of homozygosity (ROH) in affected individual’s genomes. ROH are 
defined as extended lengths of homozygous sequence on each allele that by chance have 
been inherited from both parents. A length greater than 1 Mb is considered by some to be 
significant and worth inclusion in studies, although it is possible that pathogenic alleles 
can be found in smaller regions
42
. 
Given that the human mutation rate is set around 1.2 in 10
8 
per nucleotide per 
generation, every person is likely to be a carrier of at least one pathogenic gene in the 
heterozygous state
41
. If by chance two carriers produce offspring, there will be a 25% 
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chance of having children with a homozygous genotype at that gene. The odds of 
producing offspring with long ROH increase if the parents are recently related (ie: first 
cousins), and also if they are distantly related through common ancestry. If parents are  
 
  
Figure 11: Filtering and Prioritization Framework. The basic framework works to 
decrease the number of variants and then prioritize them based on several predictive 
algorithms. The purpose of these filters is to reduce the variants to a level that can be 
manually analyzed (Figure taken Li et.al. 2012) 
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from the same population displaying founder effects, it is much more likely that alleles 
will be maintained in the population and result in ROH at a higher than normal 
frequency. Individuals are said to be autozygous for an allele when by chance they have 
inherited identical haplotypes from both parents
41
. IBD analysis using various programs 
will produce .BED files which are plain-text files containing the ROH that were found to 
be significant. These .BED files can then be used to refine the search for pathogenic 
alleles to only these regions.  
The strength of detecting true ROH is dependent upon the density of markers, 
such as SNPs, throughout the genome. A higher variant density allows for better 
resolution of the ROH start and stop positions. The effect of marker density is seen 
around centromeric regions due to a lack of markers, making centromeres commonly 
appear as extremely long ROH.  
In order to magnify the efficacy of this method, it is useful to compare ROH 
between affected individuals. If a ROH is shared between multiple individuals with the 
same condition, the gene of interest is likely to be found within. It is important to keep in 
mind that this filtering strategy can only be applied when the mode of inheritance is 
assumed to be AR.  
If AR inheritance is suspected and is the assumed model, variant filtering can 
progress beyond IBD filtering. IBD filtering can be skipped if no significant ROH were 
identified or the inheritance model is not AR. Regardless of the results of IBD filtering, 
the next step is to eliminate variants based on the assumed inheritance mode. When 
analyzing data under an AR mode, only homozygous variants should be included. 
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Although there are different variant frequency cutoff levels to determine zygosity, setting 
the range of 35-75% for heterozygous and greater than 75% for homozygous can be 
used
42
.  
Further filtering of variants eliminates variants found in variant databases and 
other public datasets. The logic behind this step is that if one is investigating rare 
phenotypes that have not been reported previously, then the pathogenic mutation of 
interest will also not be previously reported. For the same reason that exome sequencing 
is an advantageous filter, variants found only within exonic or splice-site regions are of 
interest. Exome sequencing primers typically amplify regions just outside the exonic 
sequences in order to ensure complete exonic coverage. Additionally, mapping errors can 
create false positives which are filtered out when only exonic variants are retained.  
 The last step that can be automated uses computer models to estimate the 
pathogenicity of variants. Multitudes of models are available although the most heavily 
used include SIFT
38
, Polyphen
39
, and Mutation Taster
40
. These programs use predictive 
algorithms to determine the effect a variant has on the stability, based on known 
functional and structural groups; and pathogenicity of the variant, based on the type of 
mutation (ie: transition, transversion, indel, CNV). These programs are typically used in 
conjunction with one another to get a more full idea of the mutational effects. Using 
multiple programs also helps in limiting the inaccuracy that is inherent in each individual 
algorithm.  
These processes will narrow tens of thousands of variants down to only a few 
hundred at most. Typically, filtering for the inheritance pattern excludes around 40% of 
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identified variants, selecting non-synonymous mutations eliminates another 30%, 
retaining only variants not found in databases removes 3%, while only 1% will be 
identified as pathogenic by predictive programs. Following this, manual verification and 
in-depth genetic and clinical knowledge (‘Knowledge Level’ of Figure 11) are critical in 
identifying candidate mutations. Manual verification of remaining variants takes place 
using visualization tools such as the Integrative Genomics Viewer (IGV)
 44
. IGV
44
 is the 
industry standard visualization tool, which displays information relevant to variant 
verification
44
. False positives can be identified based on many criteria including, being 
located at sequencing read starts or stops, identification in other in-lab sequences, strand 
bias, and multiple mutations in close proximity. It is then down to the investigators to 
collect additional information about the genes in which the remaining variants are found. 
Pertinent information about genes would be inclusion in any signaling pathways, known 
or inferred function of the protein product, association with other diseases, and 
phenotypic information gathered from knockout mice studies.  
 If after all these steps no candidate variants are detected, several options lie before 
the researcher: filtering criteria can be relaxed to include broader ranges of variants, 
criteria can be adjusted for a new inheritance model to be studied, or new computer tools 
can be sought. However, if a true candidate variant is identified in one or a few affected 
individuals, the study must be expanded to include many more patients. If the mutation is 
closely associated with the condition and not found in normal individuals, additional 
studies, such as knockout mouse experiments and protein functional analysis, are 
required to prove direct causality between the mutation and the disease in question. 
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Goals of Study 
 The primary purpose of this investigation is to determine candidate disease-
causing gene(s) for the two clinical cases described above. Utilizing exome sequencing 
and different variant filtering approaches, this study hopes to determine the exact 
mutation causing the shared condition of spondylocostal agenesis. The importance of 
discovering this mutation is two-fold. One, this study can provide additional information 
for the parents and immediate family that may affect their reproductive options and 
necessitate genetic screening for carrier status. Additionally, the causative mutation is 
likely to be found in a gene that has not been described to be involved in vertebral 
column development due to the simple lack of description of similar cases in the 
literature. Therefore, this study could expand the current understanding of vertebral 
column development or bone growth in general.  
 The secondary purpose of this study is to optimize a systematic pipeline 
developed for disease gene discovery using exome data at the Cedars-Sinai Genomics 
Core. Although there are multitudes of computer programs and pipelines available, it is 
necessary for every lab to customize each level of data collection and analysis in order to 
generate valid data and conclusions.  
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METHODS 
 
Sample Collection 
 
Samples and medical information were obtained through the International 
Skeletal Dysplasia Registry (ISDR) at Cedars-Sinai Medical Center. Samples were 
collected using an IRB protocol approved by Cedars-Sinai. All medical information was 
anonymized. Informed consent was obtained by parents of each proband. ISDR sample 
designations for the probands are R93-287 and R09-547A. The mother(R09-547B) and 
father(R09-547C) of R09-547A were also available and analyzed (see Figure 12A). No 
parental material was available for study of R93-287. Similarity between the two proband 
cases was determined by clinical and radiographic information compiled by ISDR.  
 
Sample Processing 
 
Whole genomic DNA was extracted from lymphoblastoid cells according to 
manufacturer protocol using the QIAamp® DNA Blood Mini QIAcube Kit (Qiagen Inc., 
Valencia, CA). Absorbance wavelength ratios of 260/230 and 260/280 were determined 
using a Nanodrop® 2000 Spectrophotometer (NanoDrop Technologies Inc., Wilmington, 
DE) to identify possible protein or chemical contamination. All four analyzed samples 
were found to have acceptable absorbance ratios. Extracted DNA was then quantitated 
using a Qubit® 2.0 fluorometer with the Qubit® dsDNA HS kit (Invitrogen, Carlsbad, 
CA). Subsequently, barcoded libraries were created using the Ion Ampliseq™ Exome 
Library Kit (Life Technologies, Inc., Grand Island, NY).  
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Sequencing 
 
Samples were then loaded onto an Ion Proton PI™ v2 chip (Life Technologies, 
Inc., Grand Island, NY) and sequenced using an Ion Proton™ Sequencer (Life 
Technologies, Inc., Grand Island, NY) to collect whole exome sequences. Additionally, 
samples were subjected to SNP array analysis using a CytoChip run on the iSCAN 
instrument (Illumina, Inc. San Diego, CA) for autozygosity analysis. 
 
Data Analysis 
 Data was analyzed using two different methods. The first method utilizes Life 
Technologies’ Ion Proton™ built-in alignment, variant caller, and annotation tool (Ion 
Reporter™) to carry out analysis. The second method utilizes a pipeline and web-based 
program called Next-Generation Sequencing Analysis Toolkit (NSAT) currently being 
developed at Cedars-Sinai Genomics Core (unpublished manuscript). The analysis 
pipeline utilizes .fastq files created by the Ion Proton™ sequencer, aligns it to the human 
reference genome (hg19) and uses GATK
34, 35, 36
 to call variants. NSAT then utilizes 
multiple annotation tools and databases, including SIFT
38
, Polyphen
39
, Mutation Taster
40
, 
UCSC Genome Browser Annotation tool
45
, 1000 Genome Project
46
, dbSNP
47
. 
 Once variants were detected and annotated, filters were applied to decrease the 
number of candidate variants. Filters were applied sequentially according to the 
framework laid out in Li et.al. 2011. The initial analyses utilized IBD filtering to 
prioritize regions of homozygosity, first uniquely and then shared between both 
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probands. Subsequent analyses examined all variants prioritizing those shared between 
probands or in genes with shared mutations.  
The next round of analyses focused on each proband separately. R09-547A was 
re-sequenced, together with R09-547B and R09-547C, to inform upon parent to offspring 
transmission, commonly called trio analysis. The term trio refers to the three genotypes 
being compared: mother, father, and offspring. All analyses were completed assuming 
first a recessive model and once that model was exhausted, a dominant model. Analyses 
were performed according to the guidelines of previously published papers
33, 34, 42, 43,
 
48, 49, 
50, 51, 52, 54, 55, 56, 57, 58, 59
. 
Manual verification of variants was achieved via visualization of .BAM files 
using IGV
44
. An example of heterozygote true positive is shown in Figure 13. Variants 
were deemed false positive if they met any of the following criteria: the majority of base-
calls had base phred quality < 20, was within three bases of the start or end of the 
majority of reads, had multiple called variants in the same read, contained a common 
variant found in three independent exomes previously ran on the same sequencer, or 
displayed no or limited strand bias. Strand bias was determined by looking at the number 
of times a variant was detected in the positive and minus read strands by the sequencer. 
Strand bias was deemed significant if the bias was greater than 35%. Variants 
demonstrating strand bias would then be designated as false positives.  
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RESULTS 
Clinical Cases 
 Due to the strikingly similar vertebral phenotype, unlike any previously described 
dysplasia or dysostosis, study of two proband cases from the ISDR database was 
investigated. The ISDR sample database, the largest collection of skeletal dysplasia 
samples and records, contains over 15,000 patients dating back to 1974. These cases 
demonstrated agenesis of thoracic and lumbar vertebrae, as well as agenesis of all but the 
first rib. Available for study were clinician notes, autopsy reports, photographs, x-rays 
and limited family histories. The clinical findings described above are summarized in 
Figures 12 and 13. 
 The first proband, R09-547A, was a 28 week old, female fetus delivered to 
Hispanic parents (see Figure 12A for pedigree). The mother was a hypertensive, morbidly 
obese, Class-B diabetic. The mother had been screened and found positive for Trisomy 
18, although no further information regarding her phenotype is available in the medical 
records. A karyotype of the fetus showed a normal 46, XX finding. The fetus was 
delivered two days after fetal demise. An autopsy was performed to investigate cause of 
intrauterine demise and congenital abnormalities. Soft-tissue evidence from the autopsy 
was severely compromised due to intrauterine decomposition. Ultrasound at 18.6 weeks 
of gestation showed a septated nuchal lymphangiocoele, subcutaneous hydrops, 
subchorionic hematoma, and contractures of the legs, hands, and feet. A later 
echocardiogram showed numerous cardiac defects, however these were not observed in 
autopsy. The chief defect was the complete agenesis of all thoracic and sacral vertebrae, 
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as well as agenesis of all but the first rib (see Figure 12B/C). Additionally, R09-547A 
demonstrated four limb pterygia of the elbow, axillae, knees, and hips. The pathologist-
of-record noted mild hypertelorism and collapsed facial features. X-rays showed an 
abnormal mandible with prognathic features. The chest exhibited slight pectus carinatum 
and the abdomen had slight ascites. The limbs and digits were artefactually shortened due 
to the pterygium. The middle and ring finger of the hands and feet demonstrated partial 
syndactyly. The ilia were fused and the sacrum was completely absent. The feet 
displayed congenital vertical talus. Microscopic investigation showed general interstitial 
edema and rib sections demonstrated abnormal epiphyseal growth plates with abnormal 
zones of endochondral ossification. 
The second proband, R93-287, was a male fetus terminated after 32 weeks 
gestation due to detection of severe congenital abnormalities. The mother and father were 
of Hispanic origin, but no information about their medical or family history was 
available. Karyotyping of this proband showed no gross chromosomal abnormalities or 
rearrangements. Preliminary ultrasound showed a two-vessel umbilicus and abnormal 
contractures of the lower limbs, while the vertebral column and ribs could not be 
detected. Autopsy of the fetus was employed to attempt to determine cause for these 
extensive congenital malformations. Again the chief abnormality was the lack of all 
lumbar vertebra and all but the first two thoracic vertebrae, as well as the sacrum. R93-
287 also presented with general subcutaneous edema and multiple organ congestion of 
the spleen, kidneys, pituitary, and brain. The neck was short and wide which continued to 
a short, wide thorax. Throughout the body there were also severe congenital anomalies,  
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A. 
Figure 12: Proband Pedigrees 
and R09-547A Radiographs. 
(A.) R09 family trio and R93 
sample were analyzed by exome 
sequencing, denoted by plus (+) 
symbol. Probands are 
represented with filled in shapes. 
Both probands died pre- or peri-
natally as denoted by crossed 
symbols. (Pedigrees created with 
Madeline 2.0 program) 
 (B.) and (C.) Radiographs of 
R09-547A demonstrate the 
common condition shared 
between R09 and R93, the lack 
of spondylocostal formation. 
B. 
C. 
A. 
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including situs inversus totalis, polysplenia, fused adrenals and kidneys (“horseshoe 
kidney”), abnormally shaped pancreas, and cardiac dextroisomerism. The cardiac defects  
also included a ventricular septal defect, overriding aorta, and a left tricuspid defect. The 
lungs were hypoplastic and congested. In addition to the skeletal findings, there was also 
a presumptive neural tube defect in the sacral region that appeared to open onto rigid 
connective and possibly neural tissue. The lower limbs exhibited defects similar to R09-
537A in that they were short due to the multiple contractures, with multiple defects of the 
hip, knee, and ankle joints.  
 
Molecular Diagnosis 
 To investigate the molecular cause of only two probands, exome sequencing was 
the fastest, most direct, and cost effective technique. Exome sequencing produced high 
quality data that met or exceeded the quality constraints necessary for this analysis (Table 
2). 
 With the available clinical data, the recessive inheritance was explored first. 
Given the extreme rarity of these cases, it was assumed that the causative alleles are not 
found at any appreciable level in the population. Continuing with this line of reasoning, it 
was thought likely that these probands were the result of recent or ancestral 
consanguinity. Therefore, autozygosity analysis was utilized to identify runs of 
homozygosity in R09-547A and R93-287. Regions larger than 1 Mb were deemed 
significant and are shown in Appendix 1. Shared regions of autozygosity are also 
displayed in Appendix 1. 
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Sample Bases 
sequenced 
(Gbp) 
Bases 
aligned 
(Gbp) 
Total # of reads 
(% ReadsUsable) 
Mean 
read 
length 
(bp) 
Mean 
depth 
(bp) 
R09 Trio 
(averaged) 
11.6 11.3 7.4x10^7 (59%) 157 59.8 
R93-287 11.7 11.4 7.3X10^7 (64%) 159 183.7 
Table 2: Sequencing and Alignment Data Quality Values. Quality values are uniform 
throughout all samples. The mean depth of coverage is markedly different due to the R09 
trio being run simultaneously on the same chip.  
 
Starting at the most specific characterization of the causative allele, shared 
autozygous regions were analyzed under an assumed recessive inheritance (Table 3). 
Manual verification revealed as much as 93% of filtered variants to be false positives 
based on one or several issues: being located at sequencing read starts or stops, 
identification in other sequence databases, strand bias, and multiple mutations in close 
proximity. 
 The differences in phenotype of each case suggested that the causative mutation 
may not be in the same gene or in the same pathway. Each proband was then analyzed 
independently under a recessive inheritance model and using significant runs of 
homozygosity (>1 Mb) as the first filtering step (Table 4). This approach yielded three 
candidates in R09-547A and eight in R93-287. With these results, we compared the 
candidate variants to variants called in three independent exomes sequenced for other 
unrelated studies using the same methods and instrument in order to account for inherent 
errors in the sequencing chemistry or instrumentation variant detection. It was found that  
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Filtering Step R09-547A R93-287 Total 
Called Variants 80656 80579 161235 
Variants found in shared autozygous regions 620 659 1279 
Recessive disease= Homozygous variants 89 37 126 
Remove variants found in dbSNP 13 26 39 
Nonsynonymous mutations: 13 26 39 
Exonic= possibly disease causing mutations 7 18 25 
Table 3: Shared Autozygosity analysis under recessive inheritance model.  
 
 
Filtering Step R09-547A R93-287 
Called Variants 80656 80579 
Variants only found in autozygous regions 1737 1989 
Recessive disease 477 117 
Remove variants in dbSNP 16 50 
Nonsynonymous mutations 16 50 
Exonic= possibly disease causing mutations 10 20 
New Genes: those not seen in previous analysis 4 13 
Manual verification  3 8 
Table 4: Independent autozygosity analysis under recessive inheritance model.  
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the candidate variants were identified in the other exomes as well, with the same signal 
pattern and quality values. The three independent exomes came from patients with no 
phenotype in similar to the probands in this study. It is highly unlikely that any mutations 
found in these independent exomes could be the causative mutation of interest for the 
spondylocostal dysostosis probands. This comparison showed that the candidate variants 
identified in this round were false positives created by inherent errors of the sequencing 
chemistry or instrument.  
 The last stage of recessive analysis opened the possibility recessive mutation in 
any part of the genome, including both homozygous and compound heterozygous 
mutations. This run took away the autozygosity filtering step and tried to locate any 
homozygous mutations in each individual independently (Table 5). Following manual 
verification of identified variants, no candidate genes were detected. Manual verification 
of variants via IGV
44
 demonstrated that the majority of false positives were rejected due 
to sequencing reaction errors at either end of amplified sequence reads. These false 
positives were always found within the first few bases of each read, including the 
independent exomes. The remaining variants were discarded due to various issues 
mentioned earlier. 
In the case of spondylocostal dysostosis, a perinatal lethal disease, it is assumed 
that the parents do not carry the causative allele if it is a dominant mutation. A dominant 
inheritance model assumes that the causative mutation must be de novo and in the 
heterozygous state in the affected individuals. Analyzing exome sequence for pathogenic, 
dominant alleles is more difficult for several reasons. Heterozygous mutations are found  
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Filtering Step R09-547A R93-287 
Called Variants 80656 80579 
Homozygous and compound heterozygous 
variants 
16520 3845 
Remove variants in dbSNP 868 1484 
Nonsynonymous mutations 12 62 
Exonic= possibly disease causing mutations 12 62 
Remove variants found in other exomes 4 8 
Manual Verification 0 0 
Table 5: Exome variant filtering under recessive inheritance model. 
 
Filter Step R09 Variants R93 Variants 
Called Variants 80657 80579 
Remove indels and synonymous mutations 31302 51282 
Dominant disease= Heterozygous Variants 
(Vfreq= 40-80%) 
25047 21156 
Remove variants in dbSNP 1099 10836 
Exonic= possibly disease causing mutations 320 1054 
Remove variants called in other exomes 307 928 
IGV
44
 Validation 63  30 
Table 6: Exome variant filtering under dominant inheritance model. 
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at a much higher frequency than homozygous mutations. Only one mutational event must 
occur, while two must occur to create a homozygous mutation. Heterozygous mutations 
are tolerated and passed on to offspring so there will be accumulation over time of 
heterozygous variants. Additionally, autozygosity mapping cannot be applied to 
heterozygous mutations because by definition, autozygous regions are runs of 
homozygosity. These facts make heterozygous analysis more difficult, evidenced by the 
bias of pathogenic gene discovery towards recessively inherited diseases
41
.  
 An alternative hypothesis would be that pathogenic allele is autosomal dominant 
heterozygous. The called variants were subjected to heterozygous data filtering (Table 6). 
Indels were removed in this analysis due to the large number generated by the instrument, 
as well the inability to definitively ascertain true from false positives. A wide range of 
values for the variant frequency was necessary in order to capture the most likely true 
positive heterozygote variants, and true positives were found throughout the entire range 
of 40-80%. Even after manual verification, a large number of variants existed as 
candidate genes.  
 As a means of verifying these candidates, R09-547A was re-sequenced and the 
parents sequenced to inform upon parent to offspring transmission, commonly called trio 
analysis. The term trio refers to the three genotypes being compared: mother, father, and 
offspring. There are many advantages to trio analysis. For one, it is possible to determine 
if the child is the offspring of these parents which is useful for the proper experimental 
design and as a sample management check. Using a trio analysis can also exclude 
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heterozygous candidate mutations based on the mutation status of the parents. If one 
parent is heterozygous or homozygous at a position, it is highly unlikely that a mutation 
found in the proband at that position is causative. This logic was applied to the candidate 
variants identified in the dominant inheritance analysis, with the result of all variants 
 
Filter Step R93 Variants R93 Genes 
Called Variants 73131 
 
Remove indels 70774 15804 
Remove synonymous mutations 8626 5321 
dominant disease= heterozygous 5559 3643 
Remove variants with dbSNP 331 330 
Exonic, splice site = possibly disease causing mutations 331 330 
Remove variants called in other exomes 306 302 
Trio Analysis: newly het nonref, inconsistent with parents 15 14 
IGV
44
 Validation-  0 0 
Table 7: R09 trio dominant analysis. 
being verified as possible combinations of inherited alleles. However, at all positions at 
least one of the parents was heterozygous. 
The newly sequenced trio was then analyzed together as a group using Ion 
Reporter™. The dominant analysis demonstrated no candidate genes. The dominant 
analysis utilized a filtering step that only retained heterozygous variant calls where 
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Table 8: R09 trio recessive analysis. 
 
neither parent has a variant. This step effectively looks for de novo mutations by 
comparing the genotypes of the parents and the proband to find inconsistencies.  
Continuing on with the trio analysis, the recessive model returned one manually 
verified candidate variant. The recessive trio analysis compared the genotypes of the 
parents and searched for variants that were homozygous or compound heterozygous in 
the proband, which were not present in the parents. The analysis revealed a variant in a  
gene named PM20D2 found at position chr6:89856255 (Figure 13). Human 
embryonic gene expression analysis revealed that PM20D2 is most highly expressed 
Filter Step R09 Variants R09 Genes 
Called Variants 73131 
 
Remove indels 70774 15804 
Remove synonymous mutations 8626 5321 
Recessive disease = Homozygous, compound heterozygous   3067 2402 
Remove variants with dbSNP 4 4 
Exonic, splice site = possibly disease causing mutations 4 4 
Remove variants called in other exomes 4 4 
Trio Analysis = newly homozygous nonref, newly compound  
                          heterozygous 
 
1 1 
IGV
44
 Validation 1 1 
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in the thyroid and prostate, with elevated expression occurring in brain, cartilage, 
and blood (Figure 14). 
 
Figure 14: Relative gene expression of PM20D2. In the human embryo, PM20D2 is 
only moderately expressed in cartilage. Skeletal dysplasia and dysostoses causative 
alleles are almost always found in genes specifically expressed at high levels in cartilage 
and bone.  
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DISCUSSION 
Clinical Diagnoses 
 
Based solely on the physical findings of R09-547A and R93-287, these probands 
constitute a severe, uncharacterized spondylocostal dysostosis demonstrating marked 
phenotypic heterogeneity. Differential diagnoses include the most severe cases on record 
of dorsolumbosacral agenesis or an unreported variation of neural tube defect. 
Dorsolumbosacral agenesis is characterized by sacral, lumbar, and rarely thoracic 
vertebral agenesis, as well as central nervous, cardiac, gastro-intestinal, and genitourinary 
defects
24
. Dorsolumbosacral agenesis is the most severe form of caudal regression 
syndrome, which typically affects only the sacral and lumbar vertebrae. It is possible that 
these probands constitute separate, distinct conditions with overlapping deformities. 
Owing to this possibility is the fact that R09-547A displayed compound syndactyly and 
situs solitus, while R93-287 had no syndactyly and presented with situs inversus totalis 
and cardiac defects. The malformations unique to each patient are usually not 
encountered in the same patient, although the presence of one congenital anomaly does 
increase the probability of other defects in the same individual. 
Aside from the mandibular defect and spondylocostal agenesis, R09-547A could 
be diagnosed as a classic case of lethal multiple pterygia syndrome (LMPS). The 
lymphangiocoele, general edema, pterygia and contractures at all four limbs point 
squarely to LMPS. Multiple cases of LMPS have been documented and causative 
mutations found in neuromuscular junction genes such as CHRNA1, CHRND, CHRNG, 
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CNTN1,DOK7, RAPSN, and SYNE1
60
. The current disease model holds that LMPS is 
caused by fetal akinesia, leading to growth defects in the musculoskeletal system
59
. With 
this hypothesis, it is entirely likely that a mutational or fetal event that leads to 
dysfunction of the spinal cord could cause LMPS. Of possible importance, R09-547A 
presented with agenesis of all thoracic vertebrae and LMPS, whereas R93-287 
demonstrated ossified T1 and T2 vertebrae and only popliteal pterygia. Therefore, it 
could be suggested that due to the malformation or complete lack of vertebral bone, 
spinal cord development was also affected, causing the LMPS-like phenotypes. There 
was no information regarding the status of the spinal cord in either individual in autopsy 
or pathology reports.  
The clinical cases that most closely resemble the phenotype of R93-287 are those 
of patients with HES7 mutations causing spondylocostal dysostosis type 4
56
. 
Spondylocostal dysostosis type 4 is characterized by vertebral segmentation defects, rib 
anomalies, spina bifida occulta, situs inversus with dextrocardia, myelomeningocele, 
short thorax, and pulmonary hypoplasia. All these features overlap with R93-287 except 
in that there is not so much vertebral segmentation defects as there is complete agenesis 
of the vertebral and rib bodies. The similarity of these cases (Figure 13) leads to the 
likely possibility that the causative mutation is either in the same gene, or more likely, in 
the same biological pathway.  
It is likely that the event leading to the agenesis of vertebrae and ribs also 
affecting spinal cord development. It is known that interruption of mesodermal cell 
migration during gastrulation leads to truncation of the vertebral column, as well as 
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multiple congenital abnormalities not compatible with life
23
. This type of developmental 
error could possible explain the phenotypes of these probands since they have flattened 
cervical vertebrae and presence of the first rib without development of the remaining 
segments. 
It must also be noted that the histologic examination of R93-287A analyzed rib 
sections, which showed abnormal zones of ossification, whereas R09-287 tibial and 
femoral sections showed no abnormalities. The histologic findings are congruent with 
what would be expected in a disorder that affects only specific bones groups. 
Presumably, it would be expected for R93-287A tibial and femoral sections to be normal 
and R93-287 rib sections to show abnormal zones of ossification. 
Additionally, disruption of schlerotome development causes segmental vertebral 
agenesis which is usually compatible with life
23
. The underlying cause of these 
schlerotome events has been linked to mutations interfering with the inductive influence 
of the notochord on schlerotome development
23
. Aberrant cell signaling causes a lack of 
somite ventralization and therefore, a deletion of vertebra in the affected area. This 
commonly leads to single or multiple vertebrae being deleted within the same region of 
the vertebral column
23
. Based on this information, the cause of the condition described in 
the probands is a failure of developmental processes during gastrulation. 
 
Candidate Gene - PM20D2 
 Peptidase M20 domain containing protein 2, PM20D2, maps to chr6: 89855766-
89875293 on the plus strand. It is found in band 6q15 and is comprised of seven exons. 
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An alternative name for the gene is aminoacylase 1-like protein 2, ACY1L2. The gene is 
expressed at high levels, 1.8 times the average gene. Three alternative transcripts have 
been detected in which two transcripts retain one intron and the other is completely 
unspliced. The gene includes peptidase dimerization, peptidase M20/M25/M40, and N-
myristolylation domains based on predicted functional analysis. It has been implicated in  
 
 
Figure 15: PM20D2 Variant Visualization for R09 Trio.  The candidate gene PM20D2 
is homozygous normal in the father(upper track), heterozygous in the mother(middle 
track), and homozygous recessive in R09-547A (bottom track). Visualized using IGV
44
. 
 
metabolic activities, having hydrolase, protein binding, and metallopeptidase molecular 
functions. Hydrolases are involved in the catalysis of the hydrolysis of many different 
bonds. The class of metallopeptidase found in PM20D2 is characterized by a structural 
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fold that may have destroyed the catalytic property of the protein while maintaining the 
ability to perform protein recognition and binding. All gene information was accessed via 
NCBI Aceview
60
. 
 It is uncertain what role, if any, this mutation could have in the phenotypes of the 
affected probands. It is possible that impaired metabolic processes could accumulate 
detrimental metabolic byproducts. The accumulation of these byproducts is known to 
cause disease, such as those in the lysosomal storage disorder among others. 
Somitogenesis is an extremely complex system of structural changes and protein 
signaling which may be affected by metabolic deficits.  
 
Biological, Technical and Analytical Limitations 
Disease gene discovery for rare, monogenic Mendelian diseases has been aptly 
likened to finding a needle in a haystack
61
. Although there are techniques and algorithms 
to assist in the search, there is still great chance of not finding the causative mutation. It is 
estimated that studies utilizing exome sequencing in addition to traditional diagnostic 
techniques identifies novel pathogenic genes in 24% of cases
62
. 
Several fixed biological factors work against the investigator. Rare diseases are 
deemed rare simply because there are very few cases to study. An obvious reason that 
rare diseases stay rare is because the mutation is not passed on to the next generation at 
any appreciable rate. The decreased reproductive fitness of affected individuals in rare 
Mendelian diseases is likely due to lethal effects before reaching child-bearing age. 
Additionally, many diseases present with unexplained patterns of inheritance and 
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penetrance due to genetic heterogeneity. Genetic heterogeneity in a specific disease can 
negate much of the power of discrete filtering due to many different mutations causing 
phenotypically similar disorders. With so few patients to study, the power of candidate 
gene detection using genomic analysis is reduced by several magnitudes. Another 
assumption in this study is that this condition is monogenic and acquired through 
Mendelian inheritance. The various approaches and filtering techniques lend exome 
sequencing experiments a refined focus not found in other types of genomic studies. 
However, the greatest strength can also be the greatest weakness if the underlying 
assumptions (ie: mode of inheritance, genomic region, type of mutation) behind the study 
design are incorrect. 
There are also many technical limitations to NGS and exome sequencing that 
make pathogenic gene discovery difficult. Commercially available exome kits are limited 
in the number of genes and exons targeted. These chemistry-based assays also have 
margins of error in sequence coverage and quality. Some template sequences are favored 
over others for amplification and detection, creating the situation where some regions are 
sequenced well above the average coverage, while others are very poorly covered. These 
issues lead to a routine lack of data for 10-15% of the entire exome
33
. Even with a 
flawless analysis pipeline, this would mean that if the disease-causing gene is in that 10-
15%, one would never be able to find the genetic cause of the disease in question. 
Injecting even more chance of missing the gene of interest is the issue that not all genes 
in the human genome have been likely identified. Many genes are identified theoretically 
using statistical algorithms, which like any probability based research will miss true 
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positives and create false positives. Exome kits also do not target other genetic elements 
such as promoters, untranslated regions, or micro-RNA; all of which have known 
consequences if mutated
47
. Additionally, exome sequencing does not detect chromosomal 
abnormalities, for example trisomy or copy number variation, nor can it measure 
epigenetic changes in the genome. Program and algorithm error is also ever-present in 
genomics research with common errors occurring at all levels of analysis. Programs that 
predict pathogenicity are useful, but are not considered to be completely reliable at this 
point in time. The limiting factor for these programs is the amount of information found 
in various protein and sequence databases. At times, these databases are not actively or 
properly curated and incorrect information can be included with valid data. Protein 
structure information, including protein folding, protein domain, and protein function, is 
lacking for many proteins. In the future, additional information in these databases will 
make predictive algorithms more robust. 
At the most basic level, instrument error intrinsic to the technology also occurs, 
although it is possible to partially correct for this by comparing to previously run 
samples. Through sequence detection, alignment, and variant calling, each level adds to 
the likelihood of false positives and uncalled variants.  
Finally, analytical errors are probable following the variant calling step. These 
occur during filtering and are due mostly to human error. For example, if incorrect 
filtering techniques are applied to the wrong inheritance pattern, it is unlikely to return 
any promising results. The filtering techniques used to analyze exome sequence data also 
has several layers of assumptions that can possibly lead to null results. Filtering steps 
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make assumptions that can impact results. By filtering out all variants already found in 
dbSNP
46
, one will eliminate the majority of the called variants in their dataset. However, 
there are pathogenic variants in databases and several common variants associated with 
various diseases
47, 49
. As these reference databases grow in size the likelihood of 
‘contamination’ by pathogenic alleles also grows47. The purpose of exome sequencing 
and variant filtering is to reduce the number of variants that need to be reviewed 
manually, introducing human error. Although there are parameters to determine true and 
false results, exome sequencing data is at the end of the pipeline analyzed based on 
human judgment.  
The biggest need in exome sequence analysis and bioinformatics in general is a 
bridge between programmer-biostatisticians and biological researchers. The vast majority 
of analysis programs are command-line based, with no convenient user interface for those 
not versed in computer languages. There is a void between these two specialties that 
requires more collaboration and insight from both sides. This collaboration would only 
serve to further scientific progress and lead to greater insight into human biology, more 
accurate diagnoses, and better outcomes for future patients. The need for more intuitive 
programs will only grow as genetic information becomes more integrated into clinical 
diagnostics and medicine. 
 
Conclusion 
The single candidate gene PM20D2 still requires follow-up analysis and 
investigation. Thorough academic information is lacking for this gene, although predicted 
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protein function and interactions are available. Knockout mouse study would be a 
straightforward method for determining the loss of function phenotype. If the mouse 
phenotype is similar to those found in our probands, protein function assays could be 
employed to determine the exact function. Furthermore, protein interaction studies would 
be valuable in order to better understand how PM20D2 causes the phenotype. The results 
of these studies may prove to be informative on early somitogenesis or bone and cartilage 
formation. 
Alternative hypotheses should also be pursued. It is possible that the true 
pathogenic allele escaped detection in this round of analysis. This could be due to any 
number of the reasons described in the previous section. Deeper exome sequencing, 
additional probands, expanded family history and samples could all increase the power of 
this investigation. More advanced biostatistical methods might be employed to increase 
automation of the analysis process.  
Regardless of the future outcome of these studies, NGS will become integrated 
and essential in future medicine. Earlier this year the Illumina® Hi Seq X Ten™ was 
unveiled, the first $1000 dollar whole genome sequencer. As demand for genomic 
information expands throughout medical research and practice, the price of whole 
genome sequencing is bound to decrease significantly in the near future. Exome 
sequencing alone has discovered over 150 pathogenic alleles in the last three years. These 
discoveries, while being satisfying for having added to the understanding of human 
biology, have the greatest impact on the patients and their families. These people are 
provided with a definitive cause for their conditions, hope for future therapeutics, and the 
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ability to make informed reproductive choices. Insights gained today through the study of 
rare conditions may lead to a better understanding of common diseases and improved 
targeted therapeutics. 
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APPENDIX 1 
 
Individual Autozygosity Regions 
R09-547A 
 
R93-287 
chr: Start-Stop  Length (bp) 
 
chr: Start-Stop  Length (bp) 
1:12683421-13785062 1101641 
 
1:12820870-13822397 1001527 
1:147826789-149989434 2162645 
 
1:92393752-94486667 2092915 
2:89427986-92050792 2622806 
 
1:98417967-100107260 1689293 
2:110420681-111564301 1143620 
 
1:103371652-104375470 1003818 
2:148209758-152844074 4634316 
 
1:110269286-111498111 1228825 
2:193366879-194437889 1071010 
 
1:120429512-145036086 24606574 
2:201478501-202845843 1367342 
 
1:147396797-150270209 2873412 
3:51137089-52210700 1073611 
 
1:173885712-175083411 1197699 
3:93632198-98107127 4474929 
 
2:82556479-83620727 1064248 
3:109462400-111260186 1797786 
 
2:87059005-88310592 1251587 
4:48348535-52881759 4533224 
 
2:90065357-92050792 1985435 
4:58655901-71917988 13262087 
 
3:49701983-52844534 3142551 
4:118650042-119932620 1282578 
 
3:90417541-93645047 3227506 
4:124512827-129160316 4647489 
 
4:48972651-52784678 3812027 
4:129825629-139486920 9661291 
 
6:44608033-45702779 1094746 
5:17757083-31049958 13292875 
 
6:58343762-61896616 3552854 
5:41513971-43230955 1716984 
 
6:145670357-146672103 1001746 
5:43242025-49646456 6404431 
 
7:74007197-75167225 1160028 
5:54334424-55414956 1080532 
 
7:123849491-125232739 1383248 
5:82189112-89248920 7059808 
 
8:6914646-8105359 1190713 
5:98134186-108512613 10378427 
 
8:43570228-49226169 5655941 
6:57093656-58354415 1260759 
 
8:50086760-51210232 1123472 
6:61973000-70781701 8808701 
 
8:99450646-100889987 1439341 
6:91398349-97192188 5793839 
 
8:103204972-115977758 12772786 
6:100900508-105682496 4781988 
 
9:40294324-44863631 4569307 
7:56761313-57789531 1028218 
 
9:102239947-110946296 8706349 
7:74121507-75175924 1054417 
 
10:46156720-47593133 1436413 
7:118572753-119579473 1006720 
 
11:37825890-39286042 1460152 
9:7812484-13485035 5672551 
 
11:91939857-98251961 6312104 
9:38756606-40215520 1458914 
 
11:98257308-101172115 2914807 
9:40585795-44863631 4277836 
 
11:131224448-134944006 3719558 
10:21544231-23038083 1493852 
 
12:111502558-113025901 1523343 
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R09-547A  R93-287 
chr: Start-Stop  Length (bp)  chr: Start-Stop  Length (bp) 
10:34247385-35809444 1562059  13:56443223-57836186 1392963 
10:52371188-59486084 7114896  13:96169686-97662381 1492695 
11:8339894-9358256 1018362  14:27596930-28984189 1387259 
11:30584613-32033826 1449213  14:106009942-107201303 1191361 
11:47912150-49048198 1136048  15:20192011-22455504 2263493 
11:50140423-51479648 1339225  16:21300997-22702769 1401772 
11:51505425-55196302 3690877  16:31640359-33828679 2188320 
12:38780793-41945090 3164297  16:66934153-68566787 1632634 
12:71100301-75849475 4749174  18:15102421-18540853 3438432 
12:77839942-89675376 11835434  19:24482072-27801814 3319742 
12:111779274-113025901 1246627  19:41810644-43372386 1561742 
14:40517426-49578405 9060979  20:32629322-34863083 2233761 
15:20192011-22754322 2562311    
15:72095711-73230849 1135138    
16:31857016-33858001 2000985    
16:67035519-68185160 1149641    
17:57997015-59366049 1369034    
19:30029436-31092096 1062660    
20:35043789-36054722 1010933    
21:18957631-26875667 7918036    
21:29804023-30871124 1067101    
 
Shared Autozygosity Regions 
 
Shared Regions of Autozygosity Length (bp) 
1:12820870-13785062 964192 
1:147826789-149989434 2162645 
3:51137089-52210700 1073611 
3:93632198-93645047 12849 
4:48972651-52784678 3812027 
6:58343762-58354415 10653 
7:74121507-75167225 1045718 
12:111779274-113025901 1246627 
15:20192011-22455504 2263493 
16:31857016-33828679 1971663 
16:67035519-68185160 1149641 
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